Major trial takes on Alzheimer's tau tangles with multiple drugs
NCT ID NCT06957418
First seen Nov 01, 2025 · Last updated May 14, 2026 · Updated 29 times
Summary
This study tests whether drugs that target tau protein, alone or with another drug (donanemab), can slow Alzheimer's in people aged 50–80 with very early symptoms. About 900 participants will receive different treatments or placebos over 30 months, with regular brain scans and memory tests. The goal is to find a safe way to reduce tau buildup and delay disease progression.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ALZHEIMER DISEASE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.